Brigitte Pegourié

9.9k total citations
49 papers, 1.7k citations indexed

About

Brigitte Pegourié is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Brigitte Pegourié has authored 49 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 23 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Brigitte Pegourié's work include Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (11 papers). Brigitte Pegourié is often cited by papers focused on Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (11 papers). Brigitte Pegourié collaborates with scholars based in France, United States and Spain. Brigitte Pegourié's co-authors include Philippe Moreau, Laurent Garderet, Michel Attal, Cyrille Hulin, Thierry Façon, Hervé Avet‐Loiseau, Jean‐Luc Harousseau, Lotfi Benboubker, Xavier Leleu and Denis Caillot and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Brigitte Pegourié

47 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brigitte Pegourié France	16	1.6k	1.1k	909	310	100	49	1.7k
Tommaso Caravita Italy	21	1.8k 1.1×	1.5k 1.3×	1.1k 1.2×	228 0.7×	94 0.9×	69	2.1k
Zvenyslava Masliak Poland	6	1.6k 1.1×	1.3k 1.1×	997 1.1×	300 1.0×	82 0.8×	9	1.9k
Dan Spoon United States	9	1.3k 0.8×	854 0.7×	671 0.7×	171 0.6×	76 0.8×	11	1.4k
Miguel‐Teodoro Hernández Spain	14	796 0.5×	597 0.5×	544 0.6×	210 0.7×	83 0.8×	44	1.2k
Karthik Ramasamy United Kingdom	18	918 0.6×	788 0.7×	614 0.7×	147 0.5×	65 0.7×	142	1.2k
Anne‐Marie Stoppa France	19	1.2k 0.7×	756 0.7×	592 0.7×	141 0.5×	216 2.2×	54	1.4k
Cristina Gasparetto United States	19	776 0.5×	656 0.6×	561 0.6×	138 0.4×	110 1.1×	93	1.1k
Stephen P. Kahanic United States	15	861 0.6×	683 0.6×	772 0.8×	195 0.6×	30 0.3×	21	1.3k
Miklós Egyed Hungary	17	1.1k 0.7×	806 0.7×	318 0.3×	982 3.2×	122 1.2×	95	1.6k
Patrizia Falco Italy	16	1.2k 0.8×	1.0k 0.9×	763 0.8×	153 0.5×	31 0.3×	41	1.4k

Countries citing papers authored by Brigitte Pegourié

Since Specialization

Citations

This map shows the geographic impact of Brigitte Pegourié's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Pegourié with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Pegourié more than expected).

Fields of papers citing papers by Brigitte Pegourié

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Pegourié. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Pegourié. The network helps show where Brigitte Pegourié may publish in the future.

Co-authorship network of co-authors of Brigitte Pegourié

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Pegourié. A scholar is included among the top collaborators of Brigitte Pegourié based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Pegourié. Brigitte Pegourié is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roussel, Murielle, Benjamin Hébraud, Cyrille Hulin, et al.. (2019). Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03). Blood. 134(Supplement_1). 3159–3159. 4 indexed citations

Thuret, Isabelle, E. Bernit, Frederic Galactéros, et al.. (2019). PF788 DATA FROM THE FRENCH REGISTRY FOR BETA‐THALASSEMIA PATIENTS. HemaSphere. 3(S1). 348–348. 2 indexed citations

Kaufman, Jonathan L., Cristina Gasparetto, Joseph Mıkhael, et al.. (2017). Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 130. 3131–3131. 12 indexed citations

Dejoie, Thomas, Daniela Lakomy, Hélène Caillon, Brigitte Pegourié, & Olivier Decaux. (2016). IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up. Annales de biologie clinique. 74(4). 429–441. 5 indexed citations

Bridoux, Frank, Brigitte Pegourié, Karine Augeul-Meunier, et al.. (2016). Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)). Blood. 128(22). 978–978. 8 indexed citations

Jakubowiak, Andrzej, Massimo Offidani, Brigitte Pegourié, et al.. (2016). Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 127(23). 2833–2840. 186 indexed citations

Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, et al.. (2015). Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. Blood. 126(23). 4219–4219. 13 indexed citations

Leblond, Véronique, Sylvie Chevret, Xavier Leleu, et al.. (2013). Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738). Blood. 122(21). 4359–4359. 2 indexed citations

Decaux, Olivier, Alain Renault, Véronique Sebille, et al.. (2012). Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients. Clinical Lymphoma Myeloma & Leukemia. 12(6). 418–422. 2 indexed citations

10.

Rodon, Philippe, Cyrille Hulin, Brigitte Pegourié, et al.. (2012). Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial. Blood. 120(21). 4044–4044. 5 indexed citations

11.

Roussel, Murielle, Hervé Avet‐Loiseau, Philippe Moreau, et al.. (2010). Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study. Blood. 116(21). 624–624. 13 indexed citations

12.

Avet‐Loiseau, Hervé, Denis Caillot, Gérald Marit, et al.. (2010). Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study. Blood. 116(21). 1944–1944. 13 indexed citations

13.

Hulin, Cyrille, Thierry Façon, Philippe Rodon, et al.. (2009). Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. Journal of Clinical Oncology. 27(22). 3664–3670. 266 indexed citations

14.

Thuret, Isabelle, Corinne Pondarré, Anderson Loundou, et al.. (2009). Complications and treatment of patients with -thalassemia in France: results of the National Registry. Haematologica. 95(5). 724–729. 69 indexed citations

15.

Joly, Philippe, et al.. (2008). Two New α-Thalassemia Point Mutations that are Undetectable by Biochemical Techniques. Hemoglobin. 32(4). 411–417. 4 indexed citations

16.

Attal, Michel, Jean‐Luc Harousseau, Serge Leyvraz, et al.. (2006). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 108(10). 3289–3294. 447 indexed citations

17.

Piccinni, Marie‐Pierre, Marie‐Christine Jacob, Thierry Bonnefoix, et al.. (1990). Production of granulopoiesis‐stimulating and ‐inhibiting activities by T cells associated with malignant cells in lymphomas. British Journal of Haematology. 74(4). 432–438. 5 indexed citations

18.

Gény, Christian, et al.. (1990). [Charcot-Marie-Tooth disease disclosed by a treatment with vincristine in familial Hodgkin's disease].. PubMed. 141(8). 709–10. 8 indexed citations

19.

Bonnefoix, Thierry, et al.. (1989). Limiting dilution analysis of the frequency of IL2 responsive T cells in lymph nodes involved by B-cell non-hodgkin's lymphomas. Leukemia Research. 13(4). 323–329. 9 indexed citations

20.

Bonnefoix, Thierry, et al.. (1987). Stimulation and inhibition of human granulopoiesis in vitro by normal and malignant T4- or T8-lymphocyte subpopulations.. PubMed. 15(6). 645–51. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact